News

DUBLIN, July 10, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the launch of a new over-the-counter (OTC) artificial tear formulation, REFRESH® REPAIR Lubricant Eye Drops. The first and only artificial tear in the U.S. formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants, REFRESH® REPAIR is the latest addition to the REFRESH® portfolio, the number one doctor-recommended brand of artificial tears. REFRESH® REPAIR tears are designed to repair and protect the eyes from the harmful effects of dry eye and improve clarity of vision.

"Our new REFRESH® artificial tear, REFRESH® REPAIR, offers eye doctors an additional option to tailor therapy to the specific needs of their patients. REFRESH® REPAIR provides improved comfort for patients with dry eye and unique osmoprotective benefits that safeguard the health of epithelial cells against hyperosmotic stress," said Jag Dosanjh, Senior Vice President, Allergan US Eye Care.

Over 33 million people in the United States suffer from dry eye symptoms, including irritation, blurred vision, sensitivity to light, burning, stinging, dryness and excessive tearing. Dry eye is often a chronic disease that can be caused by advanced age, contact lens wear, certain medications, eye diseases, other medical conditions or environmental factors. Without enough tears, the film protecting the eye can break down, creating dry spots on the cornea. In clinical studies, REFRESH® REPAIR was shown to improve signs and symptoms of dry eye and improve visual performance in dry eye patients, with low incidence of side effects such as blur and stickiness during blinking.

"As dry eye science has gotten more sophisticated over the past decade, we have come to appreciate the conditions necessary for a healthy ocular surface, which REFRESH® REPAIR is designed to support," said Marc Bloomenstein, OD. "With REFRESH® REPAIR, I can recommend a brand I trust, knowing that my patients will get the benefit of a formulation that helps promote healing of ocular surface cells so the ocular surface can function properly."

About REFRESH® REPAIR

REFRESH® REPAIR Lubricant Eye Drops are clinically proven to treat the signs and symptoms of dry eye and improve visual performance due to dry eye, while offering patients improved comfort with low incidence of visual disturbances. REFRESH® REPAIR is the only artificial tear brand formulated with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), and osmoprotectants. These restorative osmoprotectants displace salt in the tear film to safeguard epithelial cells against hyperosmotic stress, thus helping maintain the health of the ocular surface. REFRESH® REPAIR is safe to use with contact lenses. REFRESH® REPAIR Lubricant Eye Drops expand the options within the trusted REFRESH® line of artificial tears.

Learn more about REFRESH® REPAIR at www.refreshbrand.com.

Allergan: 70 Years Advancing Eye Care

As a leader in eye care, Allergan has discovered, developed, and delivered some of the most innovative products in the industry over the last 70 years. Allergan has launched over 125 eye care products and invested billions of dollars in new treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion. Our eye care pipeline includes 13 additional agents for multiple ocular conditions.

Our commitment to the well-being of patients is also reflected in philanthropy. Allergan and The Allergan Foundation support more than 150 organizations around the world working to improve lives and communities.  We remain steadfast in helping eye care providers deliver the best in patient care through innovative products and outreach programs.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended March 31, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.